{"product_id":"myriad-five-forces-analysis","title":"Myriad Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDon't Miss the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eMyriad’s Porter's Five Forces snapshot highlights competitive intensity, supplier leverage, buyer power and substitute threats, revealing where margins and growth may be constrained. It surfaces key strategic risks and opportunistic footholds for value creation. This brief preview only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore Myriad’s competitive dynamics and market pressures in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentrated sequencing and reagent vendors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCore inputs—NGS instruments, chips and proprietary reagents—are concentrated: short‑read market leaders like Illumina account for roughly three‑quarters of the installed base, giving suppliers strong pricing leverage and raising switching costs. Platform lock‑in binds assay chemistry and workflows and long validation cycles (often 6–18 months) deter rapid vendor changes. Volume commitments and co‑development agreements are routinely used to secure discounts and supply stability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized bioinformatics and cloud dependencies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVariant calling pipelines, annotation databases and secure cloud compute are core and hard to substitute; a single human genome produces ~200 GB of raw data and 2024 cloud analysis workloads drive storage\/compute spend sharply upward. Licensing and cloud bills can scale from thousands to millions annually as test volumes grow, compliance narrows vendor choice, and building in-house alternatives demands scarce bioinformatics talent (median US salary ~110,000 in 2024) and multi‑year effort.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiobanking, sample collection, and logistics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCold-chain couriers, kit manufacturers and collection-site partners materially affect Myriad’s turnaround time and sample quality; the global cold-chain market topped $300 billion in 2024, concentrating leverage in large providers. Disruptions or price hikes can compress margins and degrade service levels—validation of alternate vendors typically takes 6–12 months, slowing response. Geographic coverage and \u0026gt;90% reliability from established logistics firms amplify supplier bargaining power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkilled scientific and clinical labor\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpskilled phds clinical geneticists and licensed lab personnel are scarce in oncology women health driving wage pressure retention risk that raise operating costs bls may median for laboratory technologists was about nsgc genetic counselors near while phd scientist premiums often run above those averages training timelines slow hiring concentrate knowledge key employees.\u003e\n\u003cp\u003e\u003c\/p\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWorkforce scarcity: high\u003c\/li\u003e\n\u003cli\u003eWage pressure: median tech $62k (BLS May 2024)\u003c\/li\u003e\n\u003cli\u003eGenetic counselors: ~$85k (NSGC 2024)\u003c\/li\u003e\n\u003cli\u003eHiring lag: certification delays\u003c\/li\u003e\n\u003cli\u003eDependency: knowledge concentrated in few\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pskilled\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReference data and content providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAccess to curated variant databases, guidelines, and decision-support content directly affects report quality; public repositories like ClinVar surpassed 1.5 million variant submissions by 2024, while proprietary datasets often command premium licensing. Data-use restrictions and multi-year contracts (commonly 3–5 years) can lock pricing and limit portability, raising operating costs and vendor dependence.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLicensing cost pressure\u003c\/li\u003e\n\u003cli\u003eData portability limits\u003c\/li\u003e\n\u003cli\u003e3–5 year lock-in\u003c\/li\u003e\n\u003cli\u003ePublic vs proprietary gap (ClinVar \u0026gt;1.5M entries 2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentrated NGS supply, rising cloud costs and talent shortages squeeze genomics margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCore inputs are concentrated (Illumina ~75% installed base) creating pricing leverage and long validation cycles (6–18 months). Cloud and bioinformatics scale fast (≈200 GB raw\/genome; cloud costs scale to thousands–millions annually) and skilled staff scarcity raises wages (lab tech median $62k; genetic counselors ~$85k in 2024). Cold‑chain market \u0026gt;$300B (2024) and ClinVar \u0026gt;1.5M entries increase supplier dependence.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSupplier\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNGS vendors\u003c\/td\u003e\n\u003ctd\u003eMarket share\u003c\/td\u003e\n\u003ctd\u003eIllumina ~75%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenome data\u003c\/td\u003e\n\u003ctd\u003eRaw size\u003c\/td\u003e\n\u003ctd\u003e~200 GB\/genome\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold‑chain\u003c\/td\u003e\n\u003ctd\u003eMarket size\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$300B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLab tech\u003c\/td\u003e\n\u003ctd\u003eMedian wage\u003c\/td\u003e\n\u003ctd\u003e$62,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenetic counselors\u003c\/td\u003e\n\u003ctd\u003eMedian wage\u003c\/td\u003e\n\u003ctd\u003e~$85,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVariant DB\u003c\/td\u003e\n\u003ctd\u003eClinVar entries\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;1.5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored Porter's Five Forces analysis for Myriad that uncovers competitive drivers, buyer and supplier power, substitutes and entry threats, and highlights disruptive forces and strategic levers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA one-sheet, customizable Porter's Five Forces template that visualizes competitive pressure with an instant radar chart, requires no macros, supports scenario tabs (pre\/post regulation, new entrants), and is ready to drop into pitch decks or integrate with broader Excel dashboards.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer concentration and coverage policies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCommercial insurers, Medicare programs and large PBMs set reimbursement rates and utilization rules that materially shape Myriad’s volumes; top three PBMs control roughly 80% of the US PBM market and Medicare Advantage enrollment reached about 50% of beneficiaries in 2024. Coverage determinations can rapidly spur or suppress demand, while prior authorization adds administrative friction and increases price sensitivity. Volume concentration among payers amplifies negotiation leverage against Myriad.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProvider systems and oncology networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIntegrated delivery networks and the 72 NCI-designated cancer centers in 2024 control substantial oncology test volumes, shaping referral flows. Formularies, clinical pathways and lab stewardship programs increase price scrutiny and gatekeep molecular test adoption. Inclusion in system care protocols is pivotal for access, while large accounts routinely negotiate contracted discounts and service-level agreements.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinician switching costs and preferences\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOncologists, OB\/GYNs and psychiatrists prioritize turnaround time, report clarity and practice support; once Myriad is embedded in EHRs and lab workflows switching costs rise and price sensitivity falls, though decisive head-to-head clinical utility data or guideline changes can drive churn. Robust education and field liaison programs materially increase clinician stickiness and referral continuity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient advocacy and out-of-pocket exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePatients increasingly shop on cost as list prices for hereditary and companion genetic tests range roughly 1,000–3,000 and many face deductibles above 1,000, making price salient; financial-assistance programs and advocacy groups push payers and labs for broader, lower‑cost access, while DTC ordering modestly increases buyer choice but still depends on payer coverage for affordability.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrice salience: list prices 1,000–3,000\u003c\/li\u003e\n\u003cli\u003eHigh deductibles: many \u0026gt;1,000\u003c\/li\u003e\n\u003cli\u003eAdvocacy: drives coverage\/price pressure\u003c\/li\u003e\n\u003cli\u003eDTC: raises choice but relies on payers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal labs and reference partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGlobal labs and reference partners aggregate demand across markets, giving them leverage to negotiate transfer pricing amid currency, regulatory and reimbursement complexity; alternatives in many countries increase buyer mobility and pressure on margins. Co-branded offerings and shared investments by partners can rebalance power by aligning incentives and spreading commercialization costs, improving Myriad’s bargaining position.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAggregation increases buyer leverage\u003c\/li\u003e\n\u003cli\u003eFX, regulation, reimbursement drive price negotiation\u003c\/li\u003e\n\u003cli\u003eMarket alternatives raise switching power\u003c\/li\u003e\n\u003cli\u003eCo-branding shares risk and reduces buyer pressure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePBM and Medicare Advantage sway reimbursement; patients face $1,000–$3,000 test bills\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eConcentrated payers (top‑3 PBMs ~80%) and Medicare Advantage (~50% enrollment in 2024) set reimbursements and drive volume, giving them strong leverage over Myriad. Large IDNs and 72 NCI centers control referral flows and negotiate discounts; clinicians' EHR integration raises switching costs. Patients face list prices $1,000–$3,000 and common deductibles \u0026gt;$1,000, increasing price sensitivity.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop‑3 PBM share\u003c\/td\u003e\n\u003ctd\u003e~80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare Advantage enrollment\u003c\/td\u003e\n\u003ctd\u003e~50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eList price (genetic tests)\u003c\/td\u003e\n\u003ctd\u003e$1,000–$3,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNCI cancer centers\u003c\/td\u003e\n\u003ctd\u003e72\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eMyriad Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview of the Myriad Porter's Five Forces Analysis is the exact, fully formatted document you will receive upon purchase—no placeholders or mockups. It is the final, professionally written analysis, ready for immediate download and use. What you see here is what you get.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56162829795705,"sku":"myriad-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/myriad-five-forces-analysis.png?v=1762709669","url":"https:\/\/portersfiveforce.com\/products\/myriad-five-forces-analysis","provider":"Porter's Five Forces","version":"1.0","type":"link"}